Funding boost will take Lead Program Inhibitor forward
Pre-clinical biotech BiPER Therapeutics, (Strasbourg) a developer of first-in-class drug candidates targeting BiP protein to treat gastrointestinal cancers has raised a total of €1. Click to read more...
Source: labmate-online.com